Nov 22 (Reuters) – Pfizer Inc (PFE.N) mentioned on Monday its COVID-19 vaccine equipped solid prolonged-time interval protection against the virus in a leisurely-stage glimpse performed amongst kids feeble 12 to 15 years.

A two-dose series of the vaccine became as soon as 100% efficient against COVID-19, measured seven days through over four months after the 2nd dose, the firm mentioned.

A syringe is stuffed with a dose of Pfizer’s COVID-19 vaccine at a pop-up neighborhood vaccination middle on the Gateway World Christian Middle in Valley Plod, Original York, U.S., February 23, 2021. REUTERS/Brendan McDermid

The prolonged-time interval info will toughen planned submissions for elephantine-regulatory approval of the vaccine in the age neighborhood in the united states and worldwide.

Pfizer and BioNTech (22UAy.DE) will depend on clearance for a 30 micrograms dose of the vaccine for these feeble 12 and above.

The vaccine became as soon as authorized for emergency instruct in folk feeble 12-15 years by the U.S. Food & Drug Administration in Might perhaps well well moreover, and granted elephantine approval for instruct in folk feeble 16 and above in August.

Register now for FREE unlimited secure admission to to reuters.com

Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli

Our Requirements: The Thomson Reuters Believe Principles.

Comments to: Pfizer’s COVID-19 vaccine trial info reveals prolonged-time interval efficacy in kids

Your email address will not be published. Required fields are marked *

Attach images - Only PNG, JPG, JPEG and GIF are supported.

Login

Welcome to Typer

Brief and amiable onboarding is the first thing a new user sees in the theme.
Join Typer